No change in talc litigation risk for Johnson & Johnson, says Wells Fargo

Wells Fargo analyst Larry Biegelsen notes that the NY Times reported that Johnson & Johnson has lost its bid to overturn the $4.7B in a talc trial in St. Louis in July 2018. After checking with the company, the analyst is “able to confirm” that the decision relates to the trial judge denying Johnson & Johnson’s post trial motion to set aside the $4.7B verdict. Biegelsen understands that the company had to file this motion in order to file its actual appeal of the decision with the appellate court. As such, he believes the judge’s decision should not materially affect the overall talc situation for Johnson & Johnson. Wells Fargo has an Outperform rating on the shares.

https://thefly.com/landingPageNews.php?id=2839871